Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates

Immunology Letters

Volumn 137, Issue 1-2, 2011, Pages 46-52

  Dolimbek, Behzod Z ^a   Aoki, K Roger ^b   Atassi, M Zouhair ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Antibodies; Botulinum neurotoxin A; Immune suppression; Monomethoxypolyethylene glycol; Mouse protection assay; Synthetic peptides

Indexed keywords

ANTISERUM; BOTULINUM TOXIN A; MACROGOL; MONOMETHOXYPOLYETHYLENE GLYCOL; PEPTIDE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODY FORMATION; BOTULINUM TOXINS, TYPE A; CELLS, CULTURED; HUMANS; IMMUNIZATION; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; IMMUNOTOXINS; MICE; MICE, INBRED ICR; PEPTIDE FRAGMENTS; POLYETHYLENE GLYCOLS; TORTICOLLIS;

EID: 79954425296     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.02.002     Document Type: Article

References (31)

1. Aoki K.R., Smith L.A., Atassi M.Z. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol 2010, 30:167-187.
2. Atassi M.Z., Oshima M. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol 1999, 19:219-260.
3. Jankovic J. Botulinum toxin: clinical implications of antigenicity and immunoresistance. Scientific and therapeutic aspects of botulinum toxin 2002, 409-415. Lippincott Williams and Wilkins, Philadelphia. M. Brin, J. Hallett, Jankovic (Eds.).
4. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004, 19:S109-S115.
5. Naumann M., Toyka K.V., Mansouri Taleghani B., Ahmadpour J., Reiners K., Bigalke H. Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin. J Neurol Neurosurg Psychiatry 1998, 65:924-927.
6. Atassi M.Z. Basic immunological aspects of botulinum toxin therapy. Mov Disord 2004, 19:S68-S84.
7. Göschel H., Wohlfarth K., Frevert J., Dengler R., Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 1997, 147:96-102.
8. Greene P., Fahn S., Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994, 9:213-217.
9. Dressler D., Bigalke H., Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003, 250:967-969.
10. Comella C.L., Jankovic J., Shannon K.M., Tsui J., Swenson M., Leurgans S., et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005, 65:1423-1429.
11. Sloop R.R., Cole B.A., Escutin R.O. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997, 49:189-194.
12. Dressler D., Bigalke H. Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol 2004, 52:132-135.
13. Atassi M.Z., Dolimbek B.Z., Hayakari M., Middlebrook J.L., Whitney B., Oshima M. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species. J Protein Chem 1996, 15:691-700.
14. Atassi M.Z., Dolimbek B.Z. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J 2004, 23:39-52.
15. Dolimbek G.S., Dolimbek B.Z., Aoki K.R., Atassi M.Z. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol Invest 2005, 34:119-142.
16. Atassi M.Z., Dolimbek B.Z., Steward L.E., Aoki K.R. Molecular bases of protective immune responses against botulinum neurotoxin A-how antitoxin antibodies block its action. Crit Rev Immunol 2007, 27:319-341.
17. Atassi M.Z., Dolimbek B.Z., Steward L.E., Aoki K.R. Inhibition of botulinum neurotoxin A toxic action in vivo by synthetic synaptosome- and blocking antibody-binding regions. Protein J 2010, 29:320-327.
18. Dolimbek B.Z., Aoki K.R., Steward L.E., Jankovic J., Atassi M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 2007, 44:1029-1041.
19. Dolimbek B.Z., Steward L.E., Aoki K.R., Atassi M.Z. Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin. Mol Immunol 2008, 45:910-924.
20. Dolimbek B.Z., Steward L.E., Aoki K.R., Atassi M.Z. Regions of recognition by blocking antibodies on the light chain of BoNT/A. Antigenic structure of the entire toxin. Immunobiology 2010, 10.1016/j.imbio.2010.10.010.
21. Maruta T., Dolimbek B.Z., Aoki K.R., Steward L.E., Atassi M.Z. Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain. Protein J 2004, 23:539-552.
22. Maruta T., Dolimbek B.Z., Aoki K.R., Atassi M.Z. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies. J Neurosci Methods 2006, 151:90-96.
23. Atassi M.Z., Ruan K.H., Jinnai K., Oshima M., Ashizawa T. Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide. Proc Natl Acad Sci USA 1992, 89:5852-5856.
24. Atassi M.Z., Manshouri T. Synthesis of tolerogenic monomethoxypolyethylene glycol and polyvinyl alcohol conjugates of peptides. J Protein Chem 1991, 10:623-627.
25. Kaiser E., Colescott R.L., Bossinger C.D., Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 1970, 34:595-598.
26. Albericio F., Kneib-Cordonier N., Biancalana S., Gera L., Masada R.I., Hudson D., et al. Preparation and application of the 5-(4-(9-fluorenylmethyloxycarbonyl)aminoethyl-3 5-dimethoxyphenoxy)-valeric acid (PAL) handle for the solid-phase synthesis of C-terminal peptide amides under mild conditions. J Org Chem 1990, 55:3730-3743.
27. Oshima M., Atassi M.Z. T cells of mice treated with mPEG-myasthenogenic peptide conjugate are involved in protection against EAMG by stimulating lower pathogenic antibody responses. Autoimmunity 2000, 32:45-55.
28. Rosenberg J.S., Oshima M., Atassi M.Z. B-cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor. J Immunol 1996, 157:3192-3199.
29. Rosenberg J.S., Atassi M.Z. Intersite helper function of T cells specific for a protein epitope that is not recognized by antibodies. Immunol Invest 1997, 26:473-489.
30. Hamajima S., Atassi M.Z. B-cell activation in vitro by helper T cells specific to a protein region that is recognized both by T cells and by antibodies. Immunol Invest 1998, 27:121-134.
31. Aoki K.R. Immunologic and other properties of therapeutic botulinum toxin serotypes. Scientific and therapeutic aspects of botulinum toxin, 2002, 103-113. Lippincott Williams & Wilkins, Philadelphia. M.F. Brin, M. Hallett, J. Jankovic (Eds.).